In-licensing of ZX008 and Phase 3 trial for CDKL5 deficiency
A theme concerning the continuation of the Phase 3 clinical trial for CDKL5 deficiency involving ZX008, licensed in from Zogenix, including conduct of the trial by the licensor and incorporation into the company's development pipeline.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.